The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

C. S. Ambrose; F. Dubovsky; T. Yi; R. B. Belshe; S. Ashkenazi

doi:https://doi.org/10.1007/s10096-012-1595-9

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

C. S. Ambrose, F. Dubovsky, T. Yi, R. B. Belshe, S. Ashkenazi

Clinical Departments

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p

Original language	English
Pages (from-to)	2549-2557
Number of pages	9
Journal	European Journal of Clinical Microbiology and Infectious Diseases
Volume	31
Issue number	10
DOIs	https://doi.org/10.1007/s10096-012-1595-9
State	Published - Oct 2012

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1007/s10096-012-1595-9

Cite this

@article{47abaf2ee7fb49779870ef12f3cc7f20,

title = "The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing",

abstract = "In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p",

author = "Ambrose, {C. S.} and F. Dubovsky and T. Yi and Belshe, {R. B.} and S. Ashkenazi",

note = "Funding Information: Acknowledgments This analysis was supported by MedImmune, LLC. Editorial assistance was provided by Complete Healthcare Communications, Inc., Chadds Ford, PA, USA, and funded by MedI-mmune. Drs. Ambrose, Dubovsky, and Yi are employees of MedImmune. Dr. Belshe has served on advisory boards and as a consultant for MedImmune. Drs. Belshe and Ashkenazi have received research support and speaker compensation from MedImmune.",

year = "2012",

month = oct,

doi = "https://doi.org/10.1007/s10096-012-1595-9",

language = "الإنجليزيّة",

volume = "31",

pages = "2549--2557",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

AU - Ambrose, C. S.

AU - Dubovsky, F.

AU - Yi, T.

AU - Belshe, R. B.

AU - Ashkenazi, S.

N1 - Funding Information: Acknowledgments This analysis was supported by MedImmune, LLC. Editorial assistance was provided by Complete Healthcare Communications, Inc., Chadds Ford, PA, USA, and funded by MedI-mmune. Drs. Ambrose, Dubovsky, and Yi are employees of MedImmune. Dr. Belshe has served on advisory boards and as a consultant for MedImmune. Drs. Belshe and Ashkenazi have received research support and speaker compensation from MedImmune.

PY - 2012/10

Y1 - 2012/10

N2 - In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p

AB - In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2-17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in children with asthma aged 6-17 years have been demonstrated. However, few data are available for children younger than 6 years of age with asthma or prior wheezing. Safety and efficacy data were collected for children aged 2-5 years with asthma or prior wheezing fromtwo randomized, multinational trials of LAIV and TIV (N01,940). Wheezing, lower respiratory illness, and hospitalization were not significantly increased among children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed among LAIV recipients (p

UR - http://www.scopus.com/inward/record.url?scp=84869103013&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s10096-012-1595-9

DO - https://doi.org/10.1007/s10096-012-1595-9

M3 - مقالة

C2 - 22410646

SN - 0934-9723

VL - 31

SP - 2549

EP - 2557

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 10

ER -

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this